Bausch + Lomb Co. (NYSE:BLCO) Shares Bought by HighTower Advisors LLC

HighTower Advisors LLC increased its position in Bausch + Lomb Co. (NYSE:BLCO) by 14.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,661 shares of the company’s stock after buying an additional 3,164 shares during the quarter. HighTower Advisors LLC’s holdings in Bausch + Lomb were worth $476,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Clearline Capital LP lifted its holdings in Bausch + Lomb by 136.8% in the 2nd quarter. Clearline Capital LP now owns 712,055 shares of the company’s stock valued at $10,339,000 after acquiring an additional 411,404 shares during the last quarter. Whitebox Advisors LLC lifted its stake in Bausch + Lomb by 28.2% during the second quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company’s stock valued at $22,447,000 after purchasing an additional 339,643 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Bausch + Lomb by 31.0% during the second quarter. Point72 Asset Management L.P. now owns 647,156 shares of the company’s stock worth $9,397,000 after buying an additional 153,000 shares in the last quarter. Point72 Europe London LLP increased its holdings in shares of Bausch + Lomb by 28.9% in the second quarter. Point72 Europe London LLP now owns 653,492 shares of the company’s stock valued at $9,489,000 after buying an additional 146,583 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Bausch + Lomb during the 2nd quarter valued at $1,911,000. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Trading Up 0.3 %

Shares of BLCO stock opened at $18.00 on Friday. The business’s 50 day moving average is $19.81 and its two-hundred day moving average is $17.60. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. Bausch + Lomb Co. has a 12 month low of $13.16 and a 12 month high of $21.69. The company has a market cap of $6.34 billion, a PE ratio of -17.14, a price-to-earnings-growth ratio of 1.74 and a beta of 0.43.

Bausch + Lomb (NYSE:BLCO) last released its earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.01. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The business’s revenue was up 18.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.22 EPS. Equities analysts predict that Bausch + Lomb Co. will post 0.6 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on BLCO shares. Wells Fargo & Company upped their target price on Bausch + Lomb from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Morgan Stanley cut shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 target price for the company. in a report on Monday, December 2nd. Bank of America restated an “underperform” rating and set a $18.00 price target on shares of Bausch + Lomb in a report on Thursday, December 12th. Stifel Nicolaus lifted their price objective on shares of Bausch + Lomb from $16.00 to $19.00 and gave the stock a “hold” rating in a research report on Monday, September 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Bausch + Lomb presently has a consensus rating of “Hold” and a consensus price target of $20.58.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.